BioAlliance Pharma, an innovative company dedicated to the development of orphan oncology and to supportive care products, has received two new patents for Sitavig (acyclovir mucoadhesive tablet) from the US and South Korean patent offices. Sitavig is approved in the US and in eight European countries (Sweden, the UK, Spain, Italy, Denmark, Finland, Norway and Poland) for the treatment of recurrent labial herpes in adults.
Sitavig’s patent protection is now further enhanced with:
The issuance of a third patent family in the US based on the administration scheme, a single application of Sitavig that covers the entire herpes outbreak episode. This new patent extends Sitavig market exclusivity for two additional years, until December 2029 in Sitavig’s first commercial market.
The extension of the second patent family with a new issuance from the South Korean Patent Office. After Europe, the United States, China and Japan, the South Korean office has granted the patent based on Sitavig’s original manufacturing process, which gives the product its special adhering property.
This set of three patent families and patent applications therefore reinforces Sitavig’s market protection and gives Sitavig strong exclusivity until 2029 in key international markets.
“These grants mirror our industrial protection strategy which is to maximize the value of the products in our pipeline with the best possible exclusivity. Sitavig’s extended protection until 2029 in the US should help facilitate discussions with potential business partners,” said Aude Michel, director of Business Development BioAlliance Pharma.